Department of Women's and Children's Health, Uppsala University, Uppsala, SE-751 85, Sweden.
Section of Pediatric Surgery, University Children's Hospital, Uppsala, Sweden.
Eur J Pediatr. 2023 Jun;182(6):2775-2784. doi: 10.1007/s00431-023-04907-3. Epub 2023 Apr 5.
Previous studies suggest that Paneth cells are involved in NEC development. Defensin alpha 6 (DEFA6) and guanylate cyclase activator 2A (GUCA2A) are selective protein markers of Paneth cells. The objective was to explore DEFA6 and GUCA2A expression in intestinal tissue samples from newborn infants with and without NEC. Tissue samples from histologically intact intestine were analyzed from 70 infants: 43 underwent bowel resection due to NEC and 27 controls were operated due to conditions such as intestinal atresia, dysmotility, aganglionosis, pseudo-obstruction or volvulus. Each tissue sample was immunohistochemically stained for DEFA6 and GUCA2A. Semi-automated digital image analysis was performed to determine protein expression. Clinical data and protein expressions were compared between the groups. DEFA6 expression was lower in the NEC group (p = 0.006). Low DEFA6 correlated with risk of developing NEC in a logistic regression analysis, independently of gestational age and birth weight (OR 0.843 [CI 0.732-0.971]; p = 0.018). GUCA2A expression did not differ between the two groups.
Lower expression of DEFA6 together with intact GUCA2A expression indicates that NEC patients have well-defined Paneth cells but diminished defensin activity. Our results suggest that DEFA6 could be used as a biomarker for NEC.
• Previous studies of defensin activity in NEC have been inconsistent, showing that defensin levels may be increased or diminished in NEC. GUCA2A has to our knowledge never been studied in NEC.
• This study benchmarks two specific Paneth cell markers (DEFA6 and GUCA2A) and their activity in individuals with and without NEC. • The key finding is that the NEC group had a lower DEFA6 expression compared to the Controls, while the expression of GUCA2A did not differ between the groups.
探索肠组织样本中防御素α 6(DEFA6)和鸟苷酸环化酶激活剂 2A(GUCA2A)在患有和不患有 NEC 的新生儿中的表达情况。
对 70 名新生儿的组织样本进行分析,其中 43 名因 NEC 而行肠切除术,27 名因肠闭锁、动力障碍、无神经节细胞症、假性肠梗阻或肠扭转等情况而行手术。对每个组织样本进行 DEFA6 和 GUCA2A 的免疫组织化学染色。采用半自动数字图像分析来确定蛋白表达。比较两组间的临床数据和蛋白表达。
NEC 组的 DEFA6 表达水平较低(p = 0.006)。在逻辑回归分析中,低 DEFA6 与 NEC 发病风险相关,与胎龄和出生体重无关(OR 0.843[CI 0.732-0.971];p = 0.018)。两组间 GUCA2A 表达无差异。
DEFA6 表达降低而 GUCA2A 表达完整表明 NEC 患者具有明确的 Paneth 细胞,但防御素活性降低。我们的研究结果提示 DEFA6 可作为 NEC 的生物标志物。
回顾性研究,样本量小。
• 之前关于 NEC 中防御素活性的研究结果不一致,表明 NEC 中防御素水平可能升高或降低。GUCA2A 在 NEC 中从未被研究过。
• 本研究以两个特定的 Paneth 细胞标志物(DEFA6 和 GUCA2A)及其在患有和不患有 NEC 的个体中的活性为基准。• 主要发现是与对照组相比,NEC 组的 DEFA6 表达水平较低,而两组间 GUCA2A 的表达无差异。